Longevity Healthcare model basket

GLP-1 and the Obesity Economy

A concentrated book of incretin originators, oral-wave optionality, fill-finish suppliers, and distribution.

What is the thesis for GLP-1 and the Obesity Economy?

We own the two incretin originators, the near-term catalyst book, the oral and next-molecule optionality, the picks-and-shovels behind injectable fill-finish, and the distribution rails that monetize a chronic prescription. The thesis rests on demand-side arithmetic -- 42% US adult obesity prevalence, an accelerating Medicare coverage path, and cardio-metabolic pull-through -- meeting a supply base that is still capacity-constrained.

This is a curated QuantLink model basket. It is not a filed portfolio, not a fund, and not investment advice.

Published Apr 14, 2026. Updated Apr 14, 2026. Source: QuantLink curated model basket and FastAPI ideas endpoint.

Holdings
12
Benchmark
SPY
Status
Featured
1Y model return
+15.3%

Performance as of Nov 22, 2026.

Thesis narrative

The question

Is the incretin category priced as a late-stage specialty launch that tops out in the mid-2030s near $150B, or as a chronic metabolic franchise with cardiovascular, renal, hepatic, and neuro pull-through that re-prices the entire cost-of-care stack for the 42% of US adults who meet the obesity threshold?

Base rates

The reference class is prior chronic-disease categories that crossed from specialty into primary care: statins (1987-2005), SSRIs (1988-2004), and antihypertensives (1978-1995). In each case, the category took 8-12 years to reach terminal penetration, peak revenue landed 3-4x above consensus five years in, and the originator duopoly retained roughly 55-65% share through loss of exclusivity because formulation cycles and indication expansion extended the moat. Gross margins stayed above 80% until generic entry, and the picks-and-shovels sub-tier -- glass vials, elastomer stoppers, pre-filled syringes, cold-chain -- compounded revenue at a premium to the branded names in years four through eight because utilization scaled faster than price compressed.

The obesity category is roughly four years into a comparable curve. Injectable semaglutide and tirzepatide have reached roughly 12 million US patients; the addressable pool at current label is closer to 110 million. The imputed penetration embedded in forward consensus is around 18-22% by 2030. The SELECT and SURMOUNT cardiovascular outcome readouts have already moved the payer conversation from cosmetic to preventive; that is a discrete change in the base rate for coverage, not a marketing claim.

Healthcare has trailed SPY over the last twelve months by a wide margin -- the sector is down while the index compounded. That underperformance is the thesis. Multiples on LLY and NVO have compressed roughly 25-35% from peak on concerns about oral entrants, CMS negotiation, and compounding pharmacy substitution. The imputed-expectations gap is the setup.

Why consensus is wrong

Consensus treats the category as a pricing story. The binding variable is supply. Fill-finish capacity for GLP-1 injectables is still roughly 18-24 months behind demand; compounded versions exist only because the FDA shortage list created a legal window, and that window is closing as LLY and NVO bring new aseptic lines online. When the constraint shifts from access to script volume, the economics of the originators improve non-linearly, because marginal unit cost on a scaled aseptic line is a fraction of the gross price.

The second miss is the oral formulation cycle. The market reads an oral GLP-1 as a margin-dilutive substitute. A working reference class -- oral versus injectable insulin analogs, oral versus infused biologics in rheumatology -- suggests the oral wave expands the prescribing population by 3-4x while cannibalizing injectable volumes by roughly 20-30%. Net category TAM expands, not contracts.

Third, Medicare Part D repricing under the Inflation Reduction Act is already modeled in consensus. What is not modeled is the CMS coverage path for obesity as a standalone indication, which moves from denied to conditionally covered once cardiovascular outcome evidence is accepted. A coverage decision for the 65-plus population with established CV disease is a stepwise increase in addressable scripts that the sell-side has been treating as a binary rather than a probability distribution.

Position construction

The book has three 20% anchors, a catalyst book, a distribution sleeve, and a small-cap optionality tail.

Originator duopoly (~40%). LLY at 20% and NVO at 20% are the two molecules, the two cardiovascular outcomes datasets, and the two capacity build-outs. Owning both removes molecule-selection risk; the differentiation between tirzepatide and semaglutide matters for share within the category, not for category TAM.

Catalyst book (~46.7%). ABBV at 20% is the non-incretin adjacency -- Skyrizi, Rinvoq, and the immunology franchise that continues to compound while the market is distracted by the GLP-1 narrative; it is a ballast position whose multiple has been dragged down with the sector. AMGN at ~14.3% owns MariTide, the monthly dosing candidate whose Phase 3 readouts are the cleanest near-term catalyst outside the duopoly. PFE at ~12.4% is the oral danuglipron/next-molecule book plus the broader pipeline at a mid-single-digit free cash flow yield that requires almost no GLP-1 contribution to underwrite.

Distribution (~10.3%). CVS at ~9.3% is the PBM and retail pharmacy that dispenses the scripts, with Caremark's formulary position translating category volume into gross profit dollars regardless of which molecule wins. HIMS at ~1.0% is the direct-to-consumer cash-pay channel that captures patients outside commercial coverage.

Picks-and-shovels (~2.3%). WST at ~1.7% and STVN at ~0.6% are the elastomer stoppers, pre-filled syringes, and fill-finish capacity that every injectable dose requires. Their revenue scales with units, not price.

Next-wave and adjacency optionality (~1.0%). VKTX at ~0.3% is the oral dual-agonist and injectable VK2735 readout book. CRNX at ~0.4% is the oral somatostatin analog and broader endocrine pipeline. WW at ~0.02% is a de minimis behavioral-adherence call-option; the position is small enough that the binary outcome does not meaningfully affect the book.

Asymmetric payoff

If injectable capacity doubles by late 2027, oral formulations launch into a TAM-expanding rather than substitutive pattern, and CMS accepts obesity as a covered indication for the CV-established population, the weighted book returns roughly 22-32% annualized over three years. If the IRA negotiation cycle catches semaglutide earlier than expected and compounding persists longer, the book returns roughly -5% to +5%. If a second cardiovascular or neuro outcome readout moves the coverage conversation toward primary prevention, the right tail is 40-55% with material multiple re-rating on the originators.

At 55% base, 25% bear, and 20% bull, expected value is roughly +16 to +22% annualized against an SPY base rate near +8%. The payoff is asymmetric because the originators already trade at compressed multiples with growing cash flows, which truncates the bear case, while supply-constrained volume and TAM expansion keep the bull tail open.

Three things that would change our mind

  1. A CMS proposed rule in 2026 that explicitly excludes obesity as a covered indication for the Medicare population with established cardiovascular disease, with language indicating the exclusion survives administrative challenge.
  2. Phase 3 SURPASS-CVOT-style readouts for a non-duopoly oral incretin showing non-inferior CV outcomes at roughly half the gross price, with a commercial launch cleared for 2027 -- this would collapse the pricing premium before the originators have scaled capacity.
  3. Real-world evidence at 24-month follow-up showing muscle mass loss, regain rates above 75% off-therapy, or a durable increase in pancreatitis or thyroid signals that moves the FDA label toward a black-box warning and caps script growth.

What we're explicitly NOT betting on

We are NOT betting on a specific CMS negotiation outcome for semaglutide or tirzepatide -- the book survives a bad print because the capacity and volume story operates on a different axis than single-molecule pricing. We are NOT betting on LLY over NVO or vice versa; the 20/20 sizing is deliberate. We are NOT betting on any single oral readout from VKTX, PFE, or AMGN; each is sized as optionality, not as a core position. We are NOT betting on compounding pharmacies being shut down or preserved. We are NOT betting on a specific weight-loss percentage in a future Phase 3. The thesis requires only that obesity coverage expands, injectable supply scales, and the oral wave expands rather than contracts category TAM.

Model basket holdings

Model basket: curated equal or target weighting, not a filed portfolio. Weights are the target basket weights returned by the live ideas endpoint.

NameSymbolModel weight
Eli Lilly and CompanyLLY20.00%
AbbVie Inc.ABBV20.00%
Novo Nordisk A/SNVO20.00%
Amgen Inc.AMGN14.31%
Pfizer Inc.PFE12.39%
CVS Health CorporationCVS9.31%
Hims & Hers Health, Inc.HIMS0.96%
Viking Therapeutics, Inc.VKTX0.34%
WW International, Inc.WW0.02%
West Pharmaceutical Services, Inc.WST1.73%
Stevanato Group S.p.A.STVN0.59%
Crinetics Pharmaceuticals, Inc.CRNX0.35%

Backtested performance vs SPY

Performance is backtested from the returned tearsheet series. It reflects the model basket methodology and benchmark series, not live fund returns or a filed portfolio track record. Performance as of Nov 22, 2026.

Total Return

+15.3%

↑ SPY +3.2%

Ann. Return

+16.0%

↑ SPY +3.3%

Ann. Vol

20.5%

↑ SPY 14.5%

Sharpe

0.78

↑ SPY 0.23

Max Drawdown

-15.5%

↓ SPY -11.5%

Alpha vs SPY

+15.6%

↓ hit rate 47.5%

Performance as of Nov 22, 2026. Risk-free rate for Sharpe and Sortino: 0% (no risk-free rate applied).

Rolling Performance vs Benchmark

Portfolio Holdings

Holding
Weight
Country
Exchange
Sector
Industry
Mkt Cap
Price
1Y
1Y Trend
ABBV
ABBVAbbVie Inc.
20.0%
—
—
—
—
—
—
—
LLY
LLYEli Lilly and Company
20.0%
—
—
—
—
—
—
—
NVO
NVONovo Nordisk A/S
20.0%
—
—
—
—
—
—
—
AMGN
AMGNAmgen Inc.
14.3%
—
—
—
—
—
—
—
PFE
PFEPfizer Inc.
12.4%
—
—
—
—
—
—
—
CVS
CVSCVS Health Corporation
9.3%
—
—
—
—
—
—
—
WST
WSTWest Pharmaceutical Services, Inc.
1.7%
—
—
—
—
—
—
—
HIMS
HIMSHims & Hers Health, Inc.
1.0%
—
—
—
—
—
—
—
STVN
STVNStevanato Group S.p.A.
0.6%
—
—
—
—
—
—
—
CRNX
CRNXCrinetics Pharmaceuticals, Inc.
0.4%
—
—
—
—
—
—
—
VKTX
VKTXViking Therapeutics, Inc.
0.3%
—
—
—
—
—
—
—
WW
WWWW International, Inc.
0.0%
—
—
—
—
—
—
—

SSR performance series fallback

The table below is the server-rendered reference series behind the interactive chart. Values show the wealth index level from a 1.00 starting value, not a second 1Y return figure. Series as of Nov 22, 2026.

DateModel basket wealth indexSPY
Nov 25, 20251.0000x1.0000x
Nov 26, 20251.0057x1.0069x
Nov 28, 20251.0047x1.0124x
Dec 1, 20250.9871x1.0078x
Dec 2, 20250.9777x1.0096x
Dec 3, 20250.9844x1.0131x
Dec 4, 20250.9826x1.0139x
Dec 5, 20250.9745x1.0158x
Dec 8, 20250.9604x1.0128x
Dec 9, 20250.9523x1.0119x
Dec 10, 20250.9706x1.0186x
Dec 11, 20250.9813x1.0210x
Dec 12, 20250.9820x1.0100x
Dec 15, 20250.9994x1.0085x
Dec 16, 20250.9834x1.0057x
Dec 17, 20250.9731x0.9946x
Dec 18, 20250.9729x1.0021x
Dec 19, 20250.9837x1.0083x
Dec 22, 20250.9883x1.0145x
Dec 23, 20251.0010x1.0192x
Dec 24, 20251.0097x1.0228x
Dec 26, 20251.0094x1.0227x
Dec 29, 20251.0054x1.0190x
Dec 30, 20251.0025x1.0178x
Dec 31, 20250.9970x1.0102x
Jan 2, 20261.0077x1.0121x
Jan 5, 20261.0006x1.0188x
Jan 6, 20261.0186x1.0249x
Jan 7, 20261.0406x1.0216x
Jan 8, 20261.0261x1.0215x
Jan 9, 20261.0216x1.0282x
Jan 12, 20261.0274x1.0298x
Jan 13, 20261.0254x1.0278x
Jan 14, 20261.0263x1.0227x
Jan 15, 20261.0123x1.0255x
Jan 16, 20261.0240x1.0247x
Jan 20, 20261.0191x1.0038x
Jan 21, 20261.0328x1.0154x
Jan 22, 20261.0504x1.0207x
Jan 23, 20261.0422x1.0211x
Jan 26, 20261.0539x1.0262x
Jan 27, 20261.0383x1.0303x
Jan 28, 20261.0163x1.0302x
Jan 30, 20261.0220x1.0251x
Feb 2, 20261.0278x1.0302x
Feb 3, 20260.9835x1.0215x
Feb 4, 20260.9985x1.0165x
Feb 5, 20260.9673x1.0039x
Feb 6, 20261.0114x1.0231x
Feb 9, 20261.0077x1.0280x
Feb 10, 20260.9985x1.0253x
Feb 11, 20260.9967x1.0251x
Feb 12, 20261.0071x1.0093x
Feb 13, 20261.0167x1.0100x
Feb 17, 20261.0163x1.0116x
Feb 18, 20261.0112x1.0167x
Feb 19, 20261.0000x1.0140x
Feb 20, 20260.9910x1.0213x
Feb 23, 20260.9768x1.0109x
Feb 24, 20260.9658x1.0183x
Feb 25, 20260.9629x1.0269x
Feb 26, 20260.9574x1.0212x
Feb 27, 20260.9758x1.0163x
Mar 2, 20260.9732x1.0168x
Mar 3, 20260.9571x1.0079x
Mar 4, 20260.9702x1.0150x
Mar 5, 20260.9583x1.0093x
Mar 6, 20260.9571x0.9961x
Mar 9, 20260.9705x1.0048x
Mar 10, 20260.9618x1.0032x
Mar 11, 20260.9647x1.0019x
Mar 12, 20260.9477x0.9867x
Mar 13, 20260.9434x0.9811x
Mar 16, 20260.9490x0.9911x
Mar 17, 20260.9363x0.9937x
Mar 18, 20260.9119x0.9799x
Mar 19, 20260.9071x0.9775x
Mar 20, 20260.8968x0.9608x
Mar 23, 20260.8990x0.9709x
Mar 24, 20260.8997x0.9676x
Mar 25, 20260.9043x0.9730x
Mar 26, 20260.9037x0.9557x
Mar 27, 20260.8903x0.9394x
Mar 30, 20260.8943x0.9362x
Mar 31, 20260.9182x0.9634x
Apr 1, 20260.9246x0.9707x
Apr 2, 20260.9165x0.9716x
Apr 6, 20260.9078x0.9762x
Apr 7, 20260.9111x0.9766x
Apr 8, 20260.9303x1.0015x
Apr 9, 20260.9311x1.0072x
Apr 10, 20260.9218x1.0066x
Apr 13, 20260.9218x1.0164x
Apr 14, 20260.9305x1.0288x
Apr 15, 20260.9298x1.0369x
Apr 16, 20260.9343x1.0395x
Apr 17, 20260.9423x1.0520x
Apr 20, 20260.9344x1.0499x
Apr 21, 20260.9244x1.0431x
Apr 22, 20260.9198x1.0536x
Apr 23, 20260.9215x1.0495x
Apr 24, 20260.9248x1.0577x
Apr 27, 20260.9181x1.0595x
Apr 28, 20260.9195x1.0543x
Apr 29, 20260.9182x1.0542x
Apr 30, 20260.9564x1.0646x
May 1, 20260.9565x1.0676x
May 4, 20260.9589x1.0637x
May 5, 20260.9650x1.0722x
May 6, 20260.9760x1.0871x
May 7, 20260.9709x1.0838x
May 8, 20260.9672x1.0927x
May 11, 20260.9750x1.0952x
May 12, 20260.9913x1.0936x
May 13, 20260.9997x1.0997x
May 14, 20260.9931x1.1084x
May 15, 20260.9802x1.0950x
May 18, 20260.9719x1.0943x
May 19, 20260.9852x1.0870x
May 20, 20260.9873x1.0981x
May 21, 20260.9956x1.1003x
May 22, 20261.0041x1.1046x
May 26, 20260.9945x1.1120x
May 27, 20261.0049x1.1118x
May 28, 20261.0220x1.1179x
May 29, 20261.0159x1.1207x
Jun 1, 20260.9944x1.1237x
Jun 2, 20260.9857x1.1253x
Jun 3, 20260.9918x1.1174x
Jun 4, 20261.0236x1.1216x
Jun 5, 20261.0265x1.0926x
Jun 8, 20261.0148x1.0951x
Jun 9, 20261.0234x1.0919x
Jun 10, 20261.0210x1.0747x
Jun 11, 20261.0435x1.0929x
Jun 12, 20261.0421x1.0989x
Jun 15, 20261.0333x1.1182x
Jun 16, 20261.0304x1.1116x
Jun 17, 20261.0227x1.0977x
Jun 18, 20261.0099x1.1062x
Jun 22, 20261.0409x1.1028x
Jun 23, 20261.0525x1.0868x
Jun 24, 20261.0538x1.0862x
Jun 25, 20261.0662x1.0878x
Jun 26, 20261.0961x1.0800x
Jun 29, 20261.1051x1.0977x
Jun 30, 20261.0949x1.1063x
Jul 1, 20261.0982x1.1048x
Jul 2, 20261.1263x1.1033x
Jul 6, 20261.1045x1.1130x
Jul 7, 20261.1212x1.1077x
Jul 8, 20261.1120x1.1043x
Jul 9, 20261.1077x1.1136x
Jul 10, 20261.1036x1.1184x
Jul 13, 20261.1045x1.1098x
Jul 14, 20261.0915x1.1138x
Jul 15, 20261.1029x1.1182x
Jul 16, 20261.1265x1.1121x
Jul 17, 20261.1206x1.1011x
Jul 20, 20261.1074x1.0994x
Jul 21, 20261.1197x1.1085x
Jul 22, 20261.1060x1.1072x
Jul 23, 20261.1156x1.0936x
Jul 24, 20261.1196x1.0947x
Jul 27, 20261.1233x1.0949x
Jul 28, 20261.1522x1.0975x
Jul 29, 20261.1450x1.0806x
Jul 30, 20261.1284x1.0988x
Jul 31, 20261.1001x1.1067x
Aug 3, 20261.0904x1.1224x
Aug 4, 20261.0811x1.1427x
Aug 5, 20261.0990x1.1404x
Aug 6, 20261.1056x1.1386x
Aug 7, 20261.1183x1.1455x
Aug 10, 20261.1349x1.1452x
Aug 11, 20261.1248x1.1415x
Aug 12, 20261.1214x1.1444x
Aug 13, 20261.1258x1.1524x
Aug 14, 20261.1162x1.1501x
Aug 17, 20261.1118x1.1447x
Aug 18, 20261.1358x1.1369x
Aug 19, 20261.1685x1.1393x
Aug 20, 20261.1517x1.1297x
Aug 21, 20261.1626x1.1344x
Aug 24, 20261.1632x1.1310x
Aug 25, 20261.1716x1.1346x
Aug 26, 20261.1526x1.1349x
Aug 27, 20261.1370x1.1423x
Aug 28, 20261.1272x1.1397x
Aug 31, 20261.1270x1.1363x
Sep 1, 20261.1365x1.1285x
Sep 2, 20261.1504x1.1335x
Sep 3, 20261.1518x1.1454x
Sep 4, 20261.1366x1.1410x
Sep 8, 20261.0975x1.1347x
Sep 9, 20261.0946x1.1294x
Sep 10, 20261.0913x1.1227x
Sep 11, 20261.0846x1.1322x
Sep 14, 20261.0985x1.1272x
Sep 15, 20261.0905x1.1220x
Sep 16, 20261.0832x1.1171x
Sep 17, 20261.0956x1.1297x
Sep 18, 20261.0958x1.1284x
Sep 21, 20261.0843x1.1459x
Sep 22, 20261.0931x1.1457x
Sep 23, 20261.0806x1.1375x
Sep 24, 20261.0888x1.1365x
Sep 25, 20261.0983x1.1427x
Sep 28, 20261.0999x1.1342x
Sep 29, 20261.0960x1.1321x
Sep 30, 20261.0838x1.1298x
Oct 1, 20261.0696x1.1318x
Oct 2, 20261.0681x1.1402x
Oct 5, 20261.0713x1.1479x
Oct 6, 20261.0739x1.1542x
Oct 7, 20261.0955x1.1514x
Oct 8, 20261.0882x1.1465x
Oct 9, 20261.1005x1.1534x
Oct 12, 20261.1078x1.1527x
Oct 13, 20261.0940x1.1526x
Oct 14, 20261.1218x1.1401x
Oct 15, 20261.1437x1.1434x
Oct 16, 20261.1430x1.1307x
Oct 19, 20261.1323x1.1357x
Oct 20, 20261.1626x1.1393x
Oct 21, 20261.1523x1.1453x
Oct 22, 20261.1685x1.1318x
Oct 23, 20261.1540x1.1258x
Oct 26, 20261.1564x1.1338x
Oct 27, 20261.1539x1.1402x
Oct 28, 20261.1520x1.1441x
Nov 5, 20261.1700x1.0859x
Nov 9, 20261.1933x1.1151x
Nov 10, 20261.1967x1.1110x
Nov 11, 20261.2042x1.1256x
Nov 12, 20261.1963x1.1216x
Nov 13, 20261.2050x1.1176x
Nov 16, 20261.1996x1.0962x
Nov 17, 20261.1816x1.0851x
Nov 18, 20261.1492x1.0817x
Nov 19, 20261.1316x1.0605x
Nov 20, 20261.1245x1.0219x

Themes and category

Longevity HealthcareLongevity & HealthcareInnovation

Methodology and caveats

QuantLink fetches this idea from the live FastAPI ideas endpoints and renders the returned title, thesis, holdings, themes, benchmark, and tearsheet fields directly. Missing fields are left unavailable rather than fabricated.

Holdings are a curated model basket. They are not 13F filings, not insider filings, not adviser holdings, and not a claim that any person or fund owns the basket.

Backtested performance depends on the returned basket weights, benchmark, rebalancing assumptions, available price history, and calculation choices in the tearsheet endpoint. Backtests can differ materially from live results and do not include every cost, tax, capacity, liquidity, or execution constraint an investor may face.

Equal-weight and target-weight baskets can drift between rebalance points. Rebalancing can increase turnover, and concentrated thematic baskets can have higher drawdowns than a broad market benchmark.

Frequently asked questions

Research the stocks behind this idea

Use QuantLink's screener and company pages to inspect fundamentals, valuation, and market data after reviewing the public thesis.

Related links

QuantLink is a research tool, not investment advice. This page shows a curated model basket and backtested performance, not a filed portfolio, fund return, or recommendation to buy or sell securities.